首页> 外文期刊>Cell >Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL
【24h】

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL

机译:多倍体化调节剂的鉴定为AMKL的治疗提供了治疗靶点

获取原文
获取原文并翻译 | 示例
           

摘要

The mechanism by which cells decide to skip mitosis to become polyploid is largely undefined. Here we used a high-content image-based screen to identify small-molecule probes that induce polyploidization of megakaryocytic leukemia cells and serve as perturbagens to help understand this process. Our study implicates five networks of kinases that regulate the switch to polyploidy. Moreover, we find that dimethylfasudil (diMF, H-1152P) selectively increased polyploidization, mature cell-surface marker expression, and apoptosis of malignant megakaryocytes. An integrated target identification approach employing proteomic and shRNA screening revealed that a major target of diMF is Aurora kinase A (AURKA). We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. Our findings provide a rationale to support clinical trials of MLN8237 and other inducers of polyploidization and differentiation in AMKL.
机译:细胞决定跳过有丝分裂成为多倍体的机制在很大程度上尚不清楚。在这里,我们使用了基于图像的高内涵屏幕来识别能够诱导巨核细胞白血病细胞多倍体化并充当扰动小分子的小分子探针,以帮助理解这一过程。我们的研究涉及调节向多倍体转换的五个激酶网络。此外,我们发现二甲基法舒地尔(diMF,H-1152P)选择性增加多倍体化,成熟的细胞表面标志物表达和恶性巨核细胞的凋亡。使用蛋白质组学和shRNA筛选的综合靶标鉴定方法显示,diMF的主要靶标是极光激酶A(AURKA)。我们进一步发现,MLN8237(Alisertib)是AURKA的选择性抑制剂,可在急性巨核细胞白血病(AMKL)胚芽中诱导多倍体化和成熟巨核细胞标志物的表达,并在体内显示出强大的抗AMKL活性。我们的发现为支持MLN8237和AMKL多倍体化和分化诱导剂的临床试验提供了理论依据。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号